Despite dose-limiting thrombocytopaenia, BCL-XL antagonism has shown encouraging results in certain solid tumours.1238 Combination trials with Navitoclax and kinase inhibitors (MEK, RAF and BRAF) are underway for advanced or metastatic solid tumours, including small-cell lung, colon, pancreatic, rectal and liver cancer. This evidence concerns the gene BCL2L1 and liver cancer.